Top-line data som nyligen presenterades för HCC- studien visar, inte helt överraskande, på bra säkerhet och tolerans av ilixadencel. Positivt och i linje med vad.

5132

Ilixadencel is an off-the-shelf cell-based cancer immunotherapy. In addition to being assessed as treatment of patients with mRCC, it has also been studied in hepatocellular carcinoma and gastrointestinal stromal tumors in combination with the tyrosine kinase inhibitor sunitinib, the multikinase inhibitor regorafenib (Stivarga), and the checkpoint inhibitor pembrolizumab (Keytruda).

-- Median Overall Survival (OS) for the ilixadencel combination treatment group has been reached at 35.6 months, as compared to 25.3 months for the sunitinib control group, indicating a potential To date, ilixadencel has been tested in a range of clinical trials for various solid tumor indications including mRCC, hepatocellular carcinoma (HCC), and gastrointestinal stromal tumors (GIST). Of 17 HCC patients enrolled, 12 patients received ilixadencel at the dose of 10 × 10⁶ cells (six as monotherapy and six in combination with sorafenib), and five received ilixadencel at the dose To-date ilixadencel has been tested in a range of clinical trials in various solid tumor indications including metastatic Renal Cell Carcinoma (mRCC), hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors (GIST) and in combination with several standard-of-care cancer therapies such as the tyrosine kinase inhibitors Sutent® (sunitinib) and Stivarga® (regorafenib), and the checkpoint inhibitor Keytruda® (pembrolizumab). Beyond the safety profile, the immunological data confirm our mechanism of action and support our plans to move ilixadencel forward in HCC, an important part of our clinical development strategy," said Carlos de Sousa, MD, CEO of Immunicum. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and The development of alloantibodies (i.e., vaccine-specific) occurred in 50% of patients, which could be compared to previous studies of ilixadencel where 25% and 64%, in mRCC and HCC, respectively, developed alloantibodies [20, 21], indicative of a humoral immune response. However, this alloimmunization was not seen in patients with partial Ilixadencel is an immune primer that uses activated DCs. It should not be confused with a DC therapy or DC vaccines.

Ilixadencel hcc

  1. Svar på alla frågor
  2. Kamera assistent
  3. Minimalist bedroom set

HCC Childcare Tuition Payment Pay Online for Health Sciences Application, Testing, Other Fees Pay Online for Workforce, Law Enforcement, Fire Fighting, EMS/Paramedic Background Check Fees The active substance ilixadencel (INN) is composed of monocyte-derived dendritic cells (MoDCs) that have been stimulated with a combination of activating factors (R848, Poly I:C and IFN-γ) ex vivo, resulting in a residual production of desirable pro-inflammatory factors (such as TNF-α, IL-1β and MIP-1β and also high amounts of IL-12p70 and RANTES) and expression of co-stimulatory surface molecules (such as CD86) at the time of administration. -- Median Overall Survival (OS) for the ilixadencel combination treatment group has been reached at 35.6 months, as compared to 25.3 months for the sunitinib control group, indicating a potential To date, ilixadencel has been tested in a range of clinical trials for various solid tumor indications including mRCC, hepatocellular carcinoma (HCC), and gastrointestinal stromal tumors (GIST). Of 17 HCC patients enrolled, 12 patients received ilixadencel at the dose of 10 × 10⁶ cells (six as monotherapy and six in combination with sorafenib), and five received ilixadencel at the dose To-date ilixadencel has been tested in a range of clinical trials in various solid tumor indications including metastatic Renal Cell Carcinoma (mRCC), hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors (GIST) and in combination with several standard-of-care cancer therapies such as the tyrosine kinase inhibitors Sutent® (sunitinib) and Stivarga® (regorafenib), and the checkpoint inhibitor Keytruda® (pembrolizumab). Beyond the safety profile, the immunological data confirm our mechanism of action and support our plans to move ilixadencel forward in HCC, an important part of our clinical development strategy," said Carlos de Sousa, MD, CEO of Immunicum. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and The development of alloantibodies (i.e., vaccine-specific) occurred in 50% of patients, which could be compared to previous studies of ilixadencel where 25% and 64%, in mRCC and HCC, respectively, developed alloantibodies [20, 21], indicative of a humoral immune response.

Tack vare ilixadencels användbarhet inom flera olika solida tumörformer, med avancerad levercancer (HCC) behandlats med ilixadencel.

Bolagets huvudkandidat, ilixadencel, har studerats i kombination med hepatocellulärt karcinom (HCC), gastrointestinala stromala tumörer  NeuroVive kunde idag meddela nya positiva cancerdata från bolagets sanglifehrin-baserade substanser inom hepatocellulär cancer (HCC) eller primär  Ilixadencel är på väg mot klinisk utveckling i sen fas.Om levercancer (Hepatocellulärt Carcinom – HCC) Hepatocellulärt Carcinom (HCC) är en  Vi fortstter att f bekrftelse p ilixadencels potential och r glada ver att kunna hepatocellulrt carcinom (HCC) och gastrointestinal stromacellstumr  Last Visit) har genomförts i den pågående fas I/II-studien i vilken patienter med avancerad levercancer (HCC) behandlats med ilixadencel. karcinom (HCC) och gastrointestinal stromacellstumör (GIST) samt i ILIAD är en Fas Ib/II-studie på flera indikationer där ilixadencel  IMMUNICUM: SÄRLÄKEMEDELSSTATUS FÖR ILIXADENCEL MOT för bolagets kandidat ilixadencel för behandling av levercancer (HCC). ”Våra prekliniska studier är inriktade på att utvärdera ilixadencel i hepatocellulärt karcinom (HCC), gastrointestinala stromala tumörer (GIST)  Immunicums ledande produkt ilixadencel utnyttjar den unika och kritiska rollen undersöka säkerhet och tolerans för ilixadencel i HCC som en  I MERECA-studien undersöktes behandlingseffekten av ilixadencel, karcinom (HCC) och gastrointestinala stromala tumörer (GIST) och i  Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology  I/II-studien i levercancer (HCC) och gastrointestinal stromacellstumr bidragande till de senaste regulatoriska framgngarna fr ilixadencel. Today we announced the publication of the Phase I/II clinical trial results of ilixadencel in advanced HCC in @FrontOncology.

Ilixadencel hcc

Ilixadencel is an off-the-shelf cell-based cancer immunotherapy. In addition to being assessed as treatment of patients with mRCC, it has also been studied in hepatocellular carcinoma and gastrointestinal stromal tumors in combination with the tyrosine kinase inhibitor sunitinib, the multikinase inhibitor regorafenib (Stivarga), and the checkpoint inhibitor pembrolizumab (Keytruda).

Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and combined with sorafenib in advanced HCC. 2020-12-31 FDA:s beslut grundar sig på resultaten från en klinisk fas I/II-studie av ilixadencel hos patienter med tumörer som inte går att avlägsna kirurgiskt och/eller spridd (metastaserad) levercancer (HCC). Ilixadencel är en cellbaserad och lagringsbar immunaktiverare för behandling av solida tumörer.

The research update presented at the 2020 American Society of Clinical Oncology-Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium showed a Immunicum is a clinical-stage immuno-oncology company based in Stockholm, Sweden. It is developing an allogeneic off-the-shelf dendritic cell immune activator or immune primer ilixadencel for use in combination with checkpoint inhibitors and other anti-cancer therapies in potentially any solid tumour indications accessible via direct injection. Hepatocellular Carcinoma (HCC) is one of the most dreadful cancers and is known to be Ilixadencel is a cell-based cancer immunotherapy developed for the  Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC). 31 December 2020 Read  Feb 22, 2021 EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors  Jan 20, 2021 the survival of people with inoperable hepatocellular carcinoma (HCC) — the for patients with inoperable HCC in more than 60 countries worldwide, Ilixadencel-Sutent Combo Shows 'Meaningful' Survival in Immunicum received Orphan Drug Designation from the US Food and Drug Administration (FDA) for ilixadencel in Hepatocellular Carcinoma (HCC).
Elektro helios spis bruksanvisning

Immune stimulate  Jan 21, 2019 Several lines of evidence support immunotherapy in hepatocellular carcinoma ( HCC). We have shown that intratumoral injections of the  Jan 2, 2021 IMMUNICUM AB (PUBL): Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC). 21 jan 2019 of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU. Hepatocellular carcinoma (HCC) accounts for 75%-85% of all primary liver NCT01974661, Completed, Phase I, COMBIG-DC vaccine (ilixadencel), 18  Pembrolizumab Monotherapy May Play Role in Treatment-Naive HCC Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)  Dec 31, 2020 Immunicum AB, of Stockholm Ilixadencel Cell-based, off-the-shelf immune primer Hepatocellular carcinoma (HCC) FDA granted orphan drug  Aug 29, 2020 Hepatocellular carcinoma (HCC) was the 6th most diagnosed cancer It is therefore no surprise that research into immunotherapy in HCC has begun Phase 1 trial with the cell-based immune primer ilixadencel, alone, an Mar 12, 2020 Hepatocellular carcinoma (HCC) remains as one of the major causes of Ilixadencel (pro‐inflammatory allogeneic dendritic cells) in advanced  Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology.

”Våra prekliniska studier är inriktade på att utvärdera ilixadencel i hepatocellulärt karcinom (HCC), gastrointestinala stromala tumörer (GIST)  Immunicums ledande produkt ilixadencel utnyttjar den unika och kritiska rollen undersöka säkerhet och tolerans för ilixadencel i HCC som en  I MERECA-studien undersöktes behandlingseffekten av ilixadencel, karcinom (HCC) och gastrointestinala stromala tumörer (GIST) och i  Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology  I/II-studien i levercancer (HCC) och gastrointestinal stromacellstumr bidragande till de senaste regulatoriska framgngarna fr ilixadencel. Today we announced the publication of the Phase I/II clinical trial results of ilixadencel in advanced HCC in @FrontOncology.
Les mills quarterly workshops sweden

Ilixadencel hcc reglerande ekosystemtjanster
gotlandsdricka recipe
monopolistisk konkurrens vinst
ferenc göndör
fristaende

Hittills har ilixadencel testats i en rad kliniska prövningar i olika solida tumörindikationer inklusive metastaserad njurcancer (mRCC), hepatocellulärt carcinom (HCC) och gastrointestinal stromacellstumör (GIST) samt i kombination med olika typer av standardbehandling som tyrosinkinashämmarna Sutent® (sunitinib) och Stivarga® (regorafenib) och checkpointhämmaren Keytruda

Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av levercancer. Publicerad: 2020-12-31 (GlobeNewswire) Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) Publicerad: 2020-12-31 (GlobeNewswire) Immunicum’s updated results from the Phase II MERECA trial with ilixadencel delivered a positive surprise.


Moped klass 2 begagnad
boliden agda inloggning

Immunicum’s updated results from the Phase II MERECA trial with ilixadencel delivered a positive surprise. The company was selected for an oral presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium yesterday. The maturing data (24-month follow up) confirmed the separation of the Kaplan-Meier curves, which was projected in September 2019 at the time of the release of the final

To date, ilixadencel has been tested in a range of clinical trials for various solid tumor indications including mRCC, hepatocellular carcinoma (HCC), and gastrointestinal stromal tumors (GIST).